ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

– STP0404 is the only HIV treatment candidate that has been proven safe and has a novel mechanism capable of blocking HIV reactivation. – STP0404 is expected to enter a Phase 2a clinical trial in the United States in the fourth quarter of 2022. SEOUL, South Korea, August 3, 2022 /PRNewswire/ — ST Pharm Co., …

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022 Read More »